For use beginning 10/1/2017
This directive significantly updates instructions to inspection program personnel (IPP) in cattle establishments using advanced meat recovery (AMR) systems by incorporating instructions from FSIS Notice 05-15, Interpreting Results of FSIS Verification Sampling of Domestic Beef Product Derived from Advanced Meat Recovery Systems. Using the updated instructions, IPP now verify that all beef AMR products from any cattle including veal are free of central nervous system (CNS) tissues (i.e. brain or spinal cord) and CNS-type tissues (i.e. trigeminal ganglia or dorsal root ganglia (DRG)) in accordance with 9 CFR 318.24. Specifically, this directive also updates instructions on how to schedule tasks using the Public Health Information System (PHIS), collect AMR samples, interpret laboratory test results for CNS or CNS-type tissues, and what actions to take when noncompliant product is found.
KEY POINTS:
• This directive focuses on specific verification activities associated with production of beef AMR from cattle bones
• Beef AMR product containing CNS or CNS-type tissues is not “beef” and cannot be used as an ingredient of a “meat food product”
• VAAFM will sample only AMR product produced from beef skull or vertebral column bones because these are most likely to contain CNS tissues or CNS-type tissue and therefore eligible for sampling as identified in this directive
• Establishments are required to hold or maintain control of AMR product that VAAFM samples and tests for CNS or CNS-type tissues until results are available
This directive significantly updates instructions to inspection program personnel (IPP) in cattle establishments using advanced meat recovery (AMR) systems by incorporating instructions from FSIS Notice 05-15, Interpreting Results of FSIS Verification Sampling of Domestic Beef Product Derived from Advanced Meat Recovery Systems. Using the updated instructions, IPP now verify that all beef AMR products from any cattle including veal are free of central nervous system (CNS) tissues (i.e. brain or spinal cord) and CNS-type tissues (i.e. trigeminal ganglia or dorsal root ganglia (DRG)) in accordance with 9 CFR 318.24. Specifically, this directive also updates instructions on how to schedule tasks using the Public Health Information System (PHIS), collect AMR samples, interpret laboratory test results for CNS or CNS-type tissues, and what actions to take when noncompliant product is found.
KEY POINTS:
• This directive focuses on specific verification activities associated with production of beef AMR from cattle bones
• Beef AMR product containing CNS or CNS-type tissues is not “beef” and cannot be used as an ingredient of a “meat food product”
• VAAFM will sample only AMR product produced from beef skull or vertebral column bones because these are most likely to contain CNS tissues or CNS-type tissue and therefore eligible for sampling as identified in this directive
• Establishments are required to hold or maintain control of AMR product that VAAFM samples and tests for CNS or CNS-type tissues until results are available
File
File Format